• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

OSI-930

CAS No. 728033-96-3

OSI-930 ( OSI 930 | OSI930 )

产品货号. M15785 CAS No. 728033-96-3

一种有效的口服活性 c-Kit 和 VEGFR-2 (KDR) 双重抑制剂,IC50 分别为 15 nM 和 9 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥535 有现货
5MG ¥834 有现货
10MG ¥1418 有现货
25MG ¥2746 有现货
50MG ¥4666 有现货
100MG ¥6683 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    OSI-930
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    一种有效的口服活性 c-Kit 和 VEGFR-2 (KDR) 双重抑制剂,IC50 分别为 15 nM 和 9 nM。
  • 产品描述
    A potent, orally active, dual inhibitor of c-Kit and VEGFR-2 (KDR) with IC50 of 15 nM and 9 nM, respectively; also inhibits Lck, c-Raf, Flt1, and CSF-1R (IC50<100 nM); exhibits antitumor activity in mutant Kit-expressing HMC-1 xenograft model.Solid Tumors Phase 1 Discontinued(In Vitro):OSI-930 inhibits cell proliferation in the HMC-1 cell line with IC50 of 14 nM but has no significant effect on the growth of COLO-205 cell line that does not express constitutively active mutant receptor tyrosine kinase. OSI-930 induces apoptosis in HMC-1 cell line with an EC50 value of 34 nM. OSI-930 inactivates purified, recombinant cytochrome P450 3A4 with a Ki of 24 μM in a time- and concentration-dependent manner.(In Vivo):OSI-930 (oral gavage; once a day; 38 days; 200 mg/kg) exhibits potent antitumor activity in a broad range of preclinical xenograft models.
  • 体外实验
    OSI-930 inhibits cell proliferation in the HMC-1 cell line with IC50 of 14 nM but has no significant effect on the growth of COLO-205 cell line that does not express constitutively active mutant receptor tyrosine kinase. OSI-930 induces apoptosis in HMC-1 cell line with an EC50 value of 34 nM.OSI-930 inactivates purified, recombinant cytochrome P450 3A4 with a Ki of 24 μM in a time- and concentration-dependent manner
  • 体内实验
    OSI-930 (oral gavage; once a day; 38 days; 200 mg/kg) exhibits potent antitumor activity in a broad range of preclinical xenograft models. Animal Model:Female nu/nu CD-1 mice bearing HMC-1, NCI-SNU-5, COLO-205 and U251 xenograft models Dosage:200 mg/kg Administration:Oral gavage; once a day; 38 days Result:Showed a significant level of inhibition of Kit, KDR and CSF-1R.
  • 同义词
    OSI 930 | OSI930
  • 通路
    Angiogenesis
  • 靶点
    c-Kit
  • 受体
    C-Raf|CSF-1R|FLT1|Lck|VEGFR2?(KDR)
  • 研究领域
    Cancer
  • 适应症
    Solid Tumors

化学信息

  • CAS Number
    728033-96-3
  • 分子量
    443.4416
  • 分子式
    C22H16F3N3O2S
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    O=C(C1=C(NCC2=CC=NC3=CC=CC=C23)C=CS1)NC4=CC=C(OC(F)(F)F)C=C4
  • 化学全称
    2-Thiophenecarboxamide, 3-[(4-quinolinylmethyl)amino]-N-[4-(trifluoromethoxy)phenyl]-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Garton AJ, et al. Cancer Res. 2006 Jan 15;66(2):1015-24. 2. Yap TA, et al. Clin Cancer Res. 2013 Feb 15;19(4):909-19. 3. Patel JP, et al. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6495-9. 4. Macpherson IR, et al. Eur J Cancer. 2013 Mar;49(4):782-9.
产品手册
关联产品
  • CHMFL-KIT-031

    CHMFL-KIT-031 是一种高选择性 KIT 激酶主要 V559D 突变抑制剂,IC50/Kd 为 28/266 nM。

  • AZD2932

    AZD2932是一系列新的喹唑啉醚抑制剂,可有效抑制VEGFR-2和PDGFR,对PDGFRβ/VEGFR-2/Flt-3的IC50为4 nM/8 nM/ 7 nM。

  • INCB024360 analogue

    IDO-IN-2 是一种有效的 IDO1 抑制剂(IC50=10 nM)。